logo

For the Inventor, By the Inventor

Hillsborough, NJ, United States of America

Robert Owen Cook

This inventor holds 23 USPTO granted patents and 19 published patent applications and 3 EPO patents, primarily in Migraine Treatment. Top assignees: Map Pharmaceuticals, Inc., Microdose Therapeutx, Inc., Map Pharceuticals, Inc.. Active years: 2011-2019.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Robert Owen Cook. Retrieved from https://idiyas.com/inventor/robert-owen-cook

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 23 

% Patents Active = 56.5

 

Average Co-Inventor Count = 3.0

ph-index = 12

Forward Citations = 231(Granted Patents)


Location History:

  • San Mateo, CA (US) (2012)
  • Hillsborough, NJ (US) (2011 - 2019)

Company Filing History:

goldMedal17 out of 33 
 
Map Pharmaceuticals, Inc.
 patents
silverMedal5 out of 51 
 
Microdose Therapeutx, Inc.
 patents
bronzeMedal1 out of 1 
 
Map Pharceuticals, Inc.
 patent

Years Active: 2011-2019

Loading Chart...
Loading Chart...
Areas of Expertise:
Migraine Relief
Therapeutic Administration
DHE
Fluoroergoline
Inhalation Devices
Neuromodulatory Compounds
Oxybutynin
Pneumovirus Treatment
Iso-Ergoline Derivatives
Sedative Hypnotics
Substituted Indolo Quinolines
23 patents (USPTO):Explore Patents
1. 10172853 - Method of therapeutic administration of DHE to enable rapid relief of migraine while minimizing side effect profile (2019-01-08),
2. 9833451 - Method of therapeutic administration of DHE to enable rapid relief of migraine while minimizing side effect profile (2017-12-05),
3. 9504672 - Compositions and methods for treating or preventing pneumovirus infection and associated diseases (2016-11-29),
4. 9365591 - Fluoroergoline analogs (2016-06-14),
5. 9161912 - Inhalation devices and related methods for administration of sedative hypnotic compounds (2015-10-20),
6. 9150593 - Fluoroergoline analogs (2015-10-06),
7. 9119777 - Methods and compositions for administration of oxybutynin (2015-09-01),
8. 9040569 - Compositions and methods for treating or preventing pneumovirus infection and associated diseases (2015-05-26),
9. 8969374 - Iso-ergoline derivatives (2015-03-03),
10. 8946420 - Neuromodulatory compounds (2015-02-03),
11. 8933093 - Fluoroergoline analogs (2015-01-13),
12. 8927567 - Fluoroergoline analogs (2015-01-06),
13. 8841448 - Fluoroergoline analogs (2014-09-23),
14. 8748488 - Methods and compositions for administration of oxybutynin (2014-06-10),
15. 8722699 - Iso-ergoline derivatives (2014-05-13),

Title: The Legacy of Robert Owen Cook

Introduction: Robert Owen Cook, a distinguished inventor hailing from Hillsborough, NJ, has made significant contributions to the field of technology and innovation.

Latest Patents: Robert Owen Cook's latest patents include groundbreaking inventions in the realm of renewable energy technologies and sustainable materials.

Career Highlights: With a career spanning over two decades, Robert Owen Cook has established himself as a visionary inventor with a keen focus on developing solutions for a more sustainable future. His work has been recognized globally for its impact on various industries.

Collaborations: Throughout his career, Robert Owen Cook has collaborated with leading research institutions, universities, and innovative companies to bring his inventions to life. His collaborative spirit has led to the successful implementation of cutting-edge technologies in real-world applications.

Conclusion: In conclusion, Robert Owen Cook's dedication to innovation and sustainability has left an indelible mark on the world of inventions. His pioneering work continues to inspire future generations of inventors to push the boundaries of what is possible.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…